| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Other Events
© 2026 ARBUTUS BIOPHARMA, INC 1 WWW.ARBUTUSBIO.COM © 2026 ARBUTUS BIOPHARMA, INC CORPORATE PRESENTATION Q4 2026 NASDAQ: ABUS |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 22 Oct 2026 |
8-K: Other Events
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was ... |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 07 Oct 2026 |
Form 4: Beardsley Robert A, Director
Returned 17,948 shares to the issuer ($89.7K) |
| 07 Oct 2026 |
Form 4: Nguyen Tuan, Chief Financial Officer
Returned 48,081 shares to the issuer ($240K) |
| 07 Oct 2026 |
Form 4: Sawhney Roger, Director
Returned 17,142 shares to the issuer ($85.7K) |
| 07 Oct 2026 |
Form 4: Androski Lindsay, Director
Returned 24,655 shares to the issuer ($123K) |
| 05 Oct 2026 | SCHEDULE 13D/A |
| 05 Oct 2026 |
Form 4: Roivant Sciences Ltd., Director
Returned 8,967,383 shares to the issuer ($44.8M) |
| 01 Oct 2026 | SC TO-I/A |
| 30 Sep 2026 | SC TO-I/A |
| 23 Sep 2026 |
Form 4: Androski Lindsay, Director
Received 126,864 shares by exercise or conversion ($418K) · Gave up 82,527 shares to cover exercise price or tax ($418K) |
| 23 Sep 2026 |
Form 4: Nguyen Tuan, Chief Financial Officer
Received 293,100 shares by exercise or conversion ($1.05M) · Gave up 206,637 shares to cover exercise price or tax ($1.05M) |
| 23 Sep 2026 |
Form 4: Sawhney Roger, Director
Received 131,333 shares by exercise or conversion ($510K) · Gave up 100,508 shares to cover exercise price or tax ($510K) |
| 23 Sep 2026 |
Form 4: Beardsley Robert A, Director
Received 131,333 shares by exercise or conversion ($502K) · Gave up 99,057 shares to cover exercise price or tax ($502K) |
| 04 Sep 2026 | SCHEDULE 13G |
Loading...